Naps at Noon Linked to Mortality Risk in Older Adults, with Chenlu Gao, PhD
A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.
Related Articles
ADA Symposium Focuses on New Guidelines for SOC of Overweight and Obesity
New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.
Zimislecel Enables Insulin Independence in 10 Participants with Type 1 Diabetes
Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.
Evolving Care for T1D in Pregnancy, with Lois Donovan, MD, and Denise Feig, MD, MSc
Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.
Personalized Diabetes Prevention: Insights from 15 Years of the VA MOVE! Program, with Qiaochu Xue, PhD, MPH
Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.
ACHIEVE-1: Oral GLP-1 Agonist Orforglipron Shows Strong HbA1c, Weight Reductions
The ACHIEVE-1 trial reveals orforglipron’s potential as a breakthrough treatment for type 2 diabetes, showcasing significant improvements in glycemic control and weight loss.
STEP UP: Higher Semaglutide Doses Yield Greater Weight Loss in Obesity
Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.
STRIDE: Semaglutide Reduces Progression of PAD by 54% in Type 2 Diabetes
New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.
SLIMMER: Ecnoglutide Demosntrates Weight Loss Potential in Phase 3 Trial
A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.
ACHIEVE-1: Oral GLP-1 Agonist Orforglipron Shows Strong HbA1c, Weight Reductions
The ACHIEVE-1 trial reveals orforglipron’s potential as a breakthrough treatment for type 2 diabetes, showcasing significant improvements in glycemic control and weight loss.
American Diabetes Association
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care…